Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1396 to 1410 of 1597 results for nice quality standards or clinical guidelines

  1. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

  2. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  3. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  4. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

  5. Virtual care coordination for people diagnosed with intellectual disability and comorbidities: improving patient safety and health care outcomes

    with regular patient/carer remote contact, ongoing assessment, monitoring, clinical decision making and person-centred care planning. In...

  6. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

  7. Improving the care of head and neck cancer patients with collaborative dietetics and speech and language therapy intervention

    and optimise their function before, during and after treatment. The NICE guidelines – Improving outcomes in head and neck...

  8. Improved identification of familial hypercholesterolaemia (FH) in primary care

    Shared learning database Organisation: Medway Clinical Commissioning Group Published date: March 2015

  9. Evidence summaries: new medicines – Interim process statement (PMG1)

    Evidence summaries: new medicines – Interim process statement

  10. Guide to the methods of technology appraisal 2013 (PMG9)

    Guide to the methods of technology appraisal 2013

  11. Sexual Health in Practice Training to increase HIV testing in primary care

    interest company is an implementation partner that supports delivery of high quality and effective sexual and reproductive health care...

  12. Introducing therapy champions to improve the 24 hour approach to patient rehabilitation

    working HCA shifts. The work supports delivery of several NICE guidelines and quality standards,...

  13. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  14. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  15. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.